La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V
Department of Neurology, National Institute of Neurology C. Besta, Milan, Italy.
Eur Neurol. 1994;34(4):199-203. doi: 10.1159/000117038.
The efficacy of dexamethasone (DX) and methylprednisolone (MP) at high (HD) and low (LD) dose in acute multiple sclerosis (MS) relapses was evaluated by a double-blind trial in 31 patients followed for 1 year. DX and HDMP were similarly efficacious in promoting recovery, while LDMP was ineffective in the short-term outcome and was followed by an early clinical reactivation. The different outcomes seem to be related to different immunomodulating effects, mainly on cerebrospinal fluid (CSF) IgG synthesis and on peripheral blood and CSF CD4+ lymphocyte subsets.
通过一项双盲试验，对31例患者随访1年，评估了高剂量（HD）和低剂量（LD）地塞米松（DX）及甲泼尼龙（MP）在急性多发性硬化症（MS）复发时的疗效。DX和HDMP在促进恢复方面疗效相似，而LDMP在短期预后中无效，且随后出现早期临床复发。不同的结果似乎与不同的免疫调节作用有关，主要涉及脑脊液（CSF）IgG合成以及外周血和CSF中CD4 +淋巴细胞亚群。
